Skip to main content

Dr Blauvelt on the Comparative Durability and Safety of Biologics

In this video, Andrew Blauvelt, MD, MBA, details the differences in maintenance of response and safety of various biologic therapies for the treatment of plaque psoriasis.

Dr Blauvelt is the president of the Oregon Medical Research Center in Portland, OR. He has previously served as an investigator on various trials, including several clinical studies on the efficacy of risankizumab, an IL-23 inhibitor for the treatment of psoriasis.


To read more about the comparative efficacy of risankizumab and the latest results from Dr Blauvelt, visit our Dermatology Advances resource.


 

Back to Top